Nathan P Coussens

13PUBLICATIONS
53CO-AUTHORS
Molecular targetsPredictive and prognostic markersSolid tumoursCheminformatics and quantitative structure-activity relationshipsAtomic and molecular physics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Nov 05, 2026
Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids.

|Oct 07, 2026
Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids.

|Feb 19, 2026
Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on.

Beverly A Teicher, Li Chen, Dianne L Newton

|Sep 17, 2025
RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types.

Zahra Davoudi, Thomas S Dexheimer, Nathan P Coussens

|Jun 11, 2024
HTS384 NCI60: The Next Phase of the NCI60 Screen.

Mark W Kunkel, Nathan P Coussens, Joel Morris

|Aug 28, 2023
Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs.

Thomas S Dexheimer, Nathan P Coussens, Thomas Silvers

Pageof 3

Frequent Collaborators

8 joint publications

Thomas S Dexheimer

7 joint publications

James H Doroshow

7 joint publications

Beverly A Teicher

4 joint publications

Thomas Silvers